OPA1 and migraine disorder: We used two mouse models of migraine (Figure 3A) consisting of: (1) a single intraperitoneal injection of NTG (i.p., 10 mg/kg) mimicking an acute episodic migraine attack and (2) repeated i.p. injection of NTG (10 mg/kg, one injection every other day) mimicking chronic migraine (Pradhan et al., 2014).